Artiva Biotherapeutics (NASDAQ:ARTV) Lowered to “Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of Artiva Biotherapeutics (NASDAQ:ARTV) from a hold rating to a sell rating in a report issued on Sunday morning.

A number of other analysts have also weighed in on ARTV. Cantor Fitzgerald upped their price target on shares of Artiva Biotherapeutics from $10.00 to $40.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Friday, April 24th. Wedbush upped their price target on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research note on Monday, May 11th. HC Wainwright upped their price target on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Finally, Needham & Company LLC upped their price target on shares of Artiva Biotherapeutics from $18.00 to $41.00 and gave the stock a “buy” rating in a research note on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $39.00.

Artiva Biotherapeutics Stock Performance

Shares of NASDAQ:ARTV opened at $9.78 on Friday. The company has a 50 day moving average of $8.19 and a 200-day moving average of $5.59. The firm has a market cap of $241.76 million, a P/E ratio of -2.76 and a beta of 2.86. Artiva Biotherapeutics has a twelve month low of $1.47 and a twelve month high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). Equities research analysts forecast that Artiva Biotherapeutics will post -2.45 EPS for the current year.

Insider Buying and Selling

In other Artiva Biotherapeutics news, Director Ra Capital Management, L.P. bought 6,510,416 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was acquired at an average cost of $11.52 per share, with a total value of $74,999,992.32. Following the completion of the purchase, the director directly owned 15,203,995 shares in the company, valued at approximately $175,150,022.40. This trade represents a 74.89% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. 21.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Artiva Biotherapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Prelude Capital Management LLC acquired a new stake in Artiva Biotherapeutics during the third quarter valued at approximately $41,000. Bank of America Corp DE lifted its stake in Artiva Biotherapeutics by 225.8% during the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after purchasing an additional 11,190 shares during the last quarter. Dimensional Fund Advisors LP acquired a new stake in Artiva Biotherapeutics during the first quarter valued at approximately $131,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Artiva Biotherapeutics during the fourth quarter valued at approximately $91,000. Finally, Sanctuary Advisors LLC acquired a new stake in shares of Artiva Biotherapeutics during the first quarter valued at approximately $139,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.